Social Distancing in Chronic Migraine during the COVID-19 Outbreak: Results from a Multicenter Observational Study

Stefano, Vincenzo Di; Ornello, Raffaele; Gagliardo, Andrea; Torrente, Angelo; Illuminato, Elisa; Caponnetto, Valeria; Frattale, Ilaria; Golini, Raffaella; Felice, Chiara Di; Graziano, Francesca; Caccamo, M. L.; Ventimiglia, Davide; Iacono, Salvatore; Matarazzo, Gabriella; Armetta, Francesco; Battaglia, Giuseppe; Firenze, Alberto; Sacco, Simona; Brighina, Filippo

doi:10.3390/nu13041361

Cited by 36 publications

(51 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This parameter is important, as recently demonstrated during the pandemic when both physical activity levels and sleep quality dropped in migraine patients [ 23 ]. The link between oxidative stress, physical activity, and sleep quality could somehow reside in the CGRP system [ 12 , 13 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Luca

Baldacci

Mazzucchi

et al. 2021

JCM

View full text Add to dashboard Cite

Patients with high-frequency resistant migraine and medication-overuse headache are still the main clinical challenge in tertiary headache centers. The approval of targeted antibodies against the calcitonin gene-related peptide (CGRP) and its receptor represents a powerful instrument. In this study, we observed how biological and clinical features of resistant migraineurs responded to erenumab, fremanezumab, or galcanezumab. We found a reduction in advanced oxidation protein products (AOPP) as a biomarker of improved redox state after six months of treatment. We also found that treatment efficacy was precocious and maintained with high individual responder rates. In particular, seven out of ten patients achieved a reduction of 50% from the baseline at three months, which was maintained at six months, while about one out of our patients experienced a 75% reduction in headache frequency from the first month of treatment. The migraine disability assessment (MIDAS) and the associated fatigue, anxiety, and sleep quality also significantly improved. The allodynia symptom dropped from moderate/severe to mild/absent as a sign of central sensitization reduction. Our study confirmed the safety and efficacy of CGRP inhibition in real-life, high-challenging patients. Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Luca

Baldacci

Mazzucchi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Lastly, we lack information of physical activity or dietary habits of the study subjects during the pandemic. These lifestyle elements may have an impact on patients during the pandemic [ 17 ]. Our goal is to present findings that can be representative of the real-world impact of COVID-19 on patients with migraine, given the rather large sample size.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users

Kato

Poh²,

Horváth³

et al. 2021

BMC Neurol

View full text Add to dashboard Cite

Background The nature of COVID-19 pandemic measures has altered the clinical management of migraine, and has also created barriers to evaluate the impact of such measures of migraine patients. Using the Migraine Buddy smartphone application, we assessed the impact of the COVID-19 pandemic on migraine in users residing in the United States. Methods Migraine Buddy is a smartphone application by individuals to record their migraine headache episodes, characteristics, and coping mechanisms. For this study, anonymized self-reported data from 163,176 adult Migraine Buddy users in the United States between January 2020 and May 2020, were analyzed for migraines associated with stress. A stress-related migraine is defined as one in which stress or anxiety was reported as a trigger or symptom. A questionnaire on the impact of COVID-19 on migraine and its management was also completed by 923 users from the United States in the app between April 2020 and May 2020. Results 88% of the Migraine Buddy database extract and 84% of the respondents are female, with a mean age of 36.2 years. The proportion of stress-related migraine attacks peaked at 53% on March 21 to 23, although the number of migraine attacks decreased. This followed the declaration of the COVID-19 national emergency on March 13 and a spike in the number of COVID-19 cases in the United States. Questionnaire respondents felt that the following added more stress: social isolation (22.6%), information overdose (21.2%), access to essentials (food, medication, etc.) (18.7%), and financial concerns (17.8%). To help manage migraine during COVID-19, respondents suggested stress and diet coaching programs and resources (medical articles, etc.) (34.0%), having the option for home delivery of medication (30.6%) and tele-consulting (25.5%). Conclusion Here, we report the change in the proportion of self-reported stress-related migraine in relation to evolution of the COVID-19 pandemic, as well as its impact of migraine management. Our data will help increase the understanding of patients’ needs and help with planning and execution of mitigating strategies.

show abstract

“…A previous publication reported that the restrictions taken to control the rapid spread of COVID-19 resulted in a sudden, unprecedented change in the lifestyle of individuals, leading to negative consequences on general health ( 36 ). We recognized this problem in the decline of patients reporting regular physician care ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

Stroke Care During the First and the Second Waves of the COVID-19 Pandemic in a Community Hospital

et al. 2021

View full text Add to dashboard Cite

Objective: The coronavirus disease 2019 (COVID-19) infection may alter a stroke course; thus, we compared stroke course during subsequent pandemic waves in a stroke unit (SU) from a hospital located in a rural area.Methods: A retrospective study included all patients consecutively admitted to the SU between March 15 and May 31, 2020 (“first wave”), and between September 15 and November 30, 2020 (“second wave”). We compared demographic and clinical data, treatments, and outcomes of patients between the first and the second waves of the pandemic and between subjects with and without COVID-19.Results: During the “first wave,” 1.4% of 71 patients were hospitalized due to stroke/TIA, and 41.8% of 91 during the “second wave” were infected with SARS-CoV-2 (p < 0.001). During the “second wave,” more SU staff members were infected with COVID-19 than during the “first wave” (45.6 vs. 8.7%, p < 0.001). Nevertheless, more patients underwent intravenous thrombolysis (26.4 vs. 9.9%, p < 0.008) and endovascular thrombectomy (5.3 vs. 0.0%, p < 0.001) during the second than the first wave. Large vessel occlusion (LVO) (OR 8.74; 95% CI 1.60–47.82; p = 0.012) and higher 30-day mortality (OR 6.01; 95% CI 1.04–34.78; p = 0.045) were associated with patients infected with COVID-19. No differences regarding proportions between ischemic and hemorrhagic strokes and TIAs between both waves or subgroups with and without COVID-19 existed.Conclusion: Despite the greater COVID-19 infection rate among both SU patients and staff during the “second wave” of the pandemic, a higher percentage of reperfusion procedures has been performed then. COVID-19 infection was associated with a higher rate of the LVO and 30-day mortality.

show abstract

Social Distancing in Chronic Migraine during the COVID-19 Outbreak: Results from a Multicenter Observational Study

Cited by 36 publications

References 72 publications

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users

Stroke Care During the First and the Second Waves of the COVID-19 Pandemic in a Community Hospital

Contact Info

Product

Resources

About